

**Identification of a novel multifunctional ligand for simultaneous inhibition of
Amyloid-Beta (A β ₄₂) and chelation of zinc metal ion**

Mohsen Asadbegi¹, Amir Shamloo¹

¹*Sharif university of technology, school of mechanical engineering*

Corresponding author:

Email: shamloo@sharif.edu

Supporting information

Tables:

Table S1 Secondary structure composition of the initial configuration and the average configurations of A β during 200 ns simulation of trilateral interactions. The percentage content of the secondary structures is provided for all simulations.

| % Secondary Structure | | Coil | B-Bridge | Bend | Turn | A-Helix | 5-Helix | 3-Helix | B-Sheet |
|-----------------------|---------|--------|----------|--------|--------|---------|---------|---------|---------|
| 1Z0Q | Initial | 9.523 | 0 | 21.428 | 33.333 | 26.190 | 0 | 7.142 | 0 |
| C1 | mode I | 34.062 | 0.569 | 10.883 | 10.559 | 40.189 | 0.010 | 1.346 | 0.002 |
| | mode II | 41.328 | 0.005 | 15.455 | 5.190 | 35.070 | 0.001 | 0.571 | 0 |
| C2 | mode I | 34.049 | 0.010 | 10.201 | 11.996 | 40.181 | 0.006 | 1.177 | 0 |
| | mode II | 31.329 | 0.008 | 10.140 | 9.386 | 45.416 | 0.093 | 1.249 | 0 |
| C3 | mode I | 34.335 | 0.189 | 16.499 | 8.426 | 36.427 | 0.019 | 1.714 | 0.011 |
| | mode II | 35.390 | 0.370 | 13.531 | 6.965 | 41.183 | 0.014 | 0.168 | 0 |

Table S2 Secondary structure composition of the initial configuration and the average configurations during 200 ns simulation of A β relaxation. The percentage content of the secondary structures is provided for all simulations.

| %Secondary Structure | Coil | B-Bridge | Bend | Turn | A-Helix | 5-Helix | 3-Helix | B-Sheet |
|----------------------|--------|----------|--------|--------|---------|---------|---------|---------|
| 1Z0Q | 9.523 | 0 | 21.428 | 33.333 | 26.190 | 0 | 7.142 | 0 |
| R1 | 44.540 | 2.476 | 15.055 | 8.002 | 20.129 | 0.001 | 1.269 | 6.149 |
| R2 | 42.045 | 4.590 | 16.619 | 15.651 | 16.700 | 0.0029 | 1.935 | 0.077 |
| R3 | 53.412 | 1.447 | 19.935 | 7.315 | 13.562 | 0 | 0.376 | 1.575 |
| R4 | 37.235 | 0.883 | 18.323 | 9.972 | 27.145 | 0 | 0.770 | 3.294 |

Table S3 Top 25 receptor-ligand hydrophobic interactions by propensity(%), for the A β -ligand-Zn $^{2+}$ complex simulations. subtables of (a), (b) and (c) refer to hydrophobic interactions of C1, C2, and C3, respectively

| (a) Complex Dock 1 | | | | | | (b) Complex Dock 2 | | | | | |
|--------------------|----------|------|---------|----------|------|--------------------|----------|------|---------|----------|------|
| mode I | | | mode II | | | mode I | | | mode II | | |
| Ligand | Receptor | % | Ligand | Receptor | % | Ligand | Receptor | % | Ligand | Receptor | % |
| Met13 | Phe19 | 92.1 | Met4 | Phe20 | 76 | Met13 | Phe4 | 71 | Met4 | Ala21 | 64.2 |
| Met13 | Val40 | 74.4 | Val5 | Phe20 | 74.8 | Met4 | Val39 | 64.1 | Leu3 | Val40 | 58 |
| Met13 | Ile41 | 72.3 | Leu3 | Met35 | 74.2 | Met4 | Leu17 | 61.4 | Met4 | Leu17 | 57.5 |
| Met13 | Ala42 | 59.8 | Val5 | Leu17 | 71.3 | Met13 | Val40 | 60.5 | Met4 | Val18 | 52.5 |
| Val5 | Leu34 | 54.1 | Leu3 | Leu17 | 70.4 | Met4 | Val24 | 57.1 | Ile1 | Val40 | 48.1 |
| Met4 | Leu34 | 44.8 | Met13 | Phe19 | 69.8 | Met4 | Ile41 | 55.9 | Leu3 | Val39 | 46.5 |
| Met13 | Val39 | 43.3 | Met4 | Leu17 | 62.8 | Met13 | Ala2 | 54.4 | Leu3 | Ile41 | 45.7 |
| Met4 | Ile31 | 38.7 | Leu3 | Phe20 | 58.7 | Met4 | Ile32 | 47.4 | Ile1 | Ile41 | 39.7 |
| Met4 | Ile32 | 34.6 | Leu3 | Leu34 | 54.9 | Leu3 | Ile41 | 46.7 | Met4 | Ile41 | 36.6 |
| Met4 | Ala30 | 33.5 | Leu3 | Val24 | 47.1 | Met13 | Ala42 | 44.4 | Met4 | Val36 | 35.9 |
| Leu3 | Ile31 | 33.4 | Met4 | Met35 | 46.5 | Met4 | Ala21 | 41.7 | Met4 | Met35 | 35.6 |
| Met13 | Phe20 | 30.9 | Leu3 | Val40 | 38.2 | Met4 | Phe20 | 39.9 | Ile1 | Ala42 | 35.3 |
| Leu3 | Leu34 | 28.8 | Ile1 | Leu34 | 37 | Met4 | Val36 | 38.5 | Met4 | Val39 | 34.2 |
| Met13 | Val12 | 28.7 | Met4 | Phe4 | 33.7 | Leu3 | Leu17 | 37.7 | Met4 | Leu34 | 33.6 |
| Val5 | Ile31 | 28.6 | Met4 | Ala2 | 33.6 | Leu3 | Ala21 | 34.5 | Leu3 | Val36 | 33.1 |
| Val5 | Met35 | 28.4 | Val5 | Phe4 | 32.6 | Ile1 | Leu17 | 34 | Ile1 | Leu17 | 32.5 |
| Met13 | Leu34 | 27.3 | Met4 | Val24 | 32.2 | Ile1 | Ala21 | 33.7 | Val5 | Val18 | 32.2 |
| Val5 | Ile32 | 25.8 | Leu3 | Ala21 | 32.1 | Val5 | Val24 | 32.5 | Val5 | Met35 | 32.2 |
| Val5 | Phe19 | 25.7 | Met4 | Val40 | 31.7 | Val5 | Ile32 | 32.3 | Ile1 | Val39 | 32.1 |
| Val5 | Val39 | 24.7 | Leu3 | Val39 | 31 | Met13 | Ile41 | 30.6 | Leu3 | Met35 | 30 |
| Met4 | Met35 | 21.9 | Leu3 | Ile32 | 30.9 | Leu3 | Val24 | 28.8 | Leu3 | Leu17 | 29 |
| Met13 | Val36 | 21.6 | Val5 | Met35 | 30.8 | Ile1 | Val18 | 27.3 | Val5 | Ala21 | 28.3 |
| Val5 | Ala30 | 21.1 | Leu3 | Ile31 | 28.2 | Ile1 | Ile41 | 25.8 | Leu3 | Ala21 | 28.3 |
| Leu3 | Val39 | 19.6 | Met4 | Ala21 | 27.3 | Leu3 | Val18 | 24.9 | Ile1 | Val36 | 26.6 |
| Val5 | Val40 | 19.5 | Met13 | Phe20 | 27.1 | Ile1 | Val24 | 24.3 | Val5 | Ile41 | 25.1 |

| (C) Complex Dock 3 | | | | | |
|--------------------|----------|------|---------|----------|------|
| mode I | | | mode II | | |
| Ligand | Receptor | % | Ligand | Receptor | % |
| Val5 | Leu17 | 76.2 | Leu3 | Val39 | 89.3 |
| Val5 | Ala30 | 74.7 | Met4 | Val39 | 88.9 |
| Val5 | Ala21 | 65.1 | Val5 | Ile41 | 80.9 |
| Val5 | Val18 | 60.2 | Val5 | Val40 | 79.6 |
| Val5 | Ile31 | 46 | Met4 | Met35 | 79.4 |
| Met13 | Leu17 | 45 | Met13 | Ala42 | 73.3 |
| Met13 | Ile31 | 35.3 | Val5 | Phe20 | 72.5 |
| Met4 | Val18 | 35 | Leu3 | Ile41 | 70.4 |
| Leu3 | Val18 | 32.5 | Met4 | Ile41 | 67.9 |
| Leu3 | Leu17 | 26.7 | Met4 | Val40 | 67.4 |
| Met4 | Val24 | 24.6 | Leu3 | Phe19 | 66.9 |
| Val5 | Val24 | 20.3 | Leu3 | Phe20 | 66.3 |
| Met13 | Met35 | 17.2 | Leu3 | Val40 | 63.8 |
| Met13 | Phe4 | 17 | Leu3 | Val12 | 59 |
| Met13 | Val36 | 15.1 | Met13 | Ile41 | 52.5 |
| Met13 | Leu34 | 14.6 | Val5 | Met35 | 49.3 |
| Met4 | Ala30 | 14.4 | Val5 | Ala42 | 49.2 |
| Met13 | Ala30 | 12.8 | Met13 | Leu17 | 46.8 |
| Leu3 | Ala21 | 12.2 | Ile1 | Val39 | 46.4 |
| Met4 | Ala21 | 11.6 | Val5 | Ile31 | 45.4 |
| Met13 | Val18 | 9.1 | Met4 | Phe20 | 43.2 |
| Leu3 | Val24 | 9 | Met4 | Val36 | 40.9 |
| Leu3 | Ala30 | 8.8 | Met4 | Leu34 | 38.8 |
| Ile1 | Val18 | 8.6 | Leu3 | Phe4 | 37.9 |
| Met13 | Ala2 | 7.6 | Ile1 | Met35 | 36.2 |

Table S4 The details of top 25 H-bonds by propensity (%) between the receptor and the ligand for the A β -ligand-Zn²⁺ complex simulations. subtables of (a), (b) and (c) refer to C1, C2, and C3, respectively

| (a) Complex Dock 1 | | | | | | (b) Complex Dock 2 | | | | | |
|--------------------|----------|-------|---------|----------|--------|--------------------|----------|-------|---------|----------|-------|
| mode I | | | mode II | | | mode I | | | mode II | | |
| Donor | Acceptor | % | Donor | Acceptor | % | Donor | Acceptor | % | Donor | Acceptor | % |
| Ile1 | Glu11 | 53.41 | Lys16 | Gly7 | 110.98 | Gly10 | Val39 | 64.13 | Gly7 | His14 | 38.89 |
| Met13 | Phe19 | 28.33 | Lys16 | Gly9 | 98.63 | Asn11 | Val39 | 29.87 | Gly9 | Gly9 | 35.5 |
| Gly10 | Leu34 | 26.58 | Lys16 | Gly6 | 82.35 | Ile41 | Asn11 | 25.35 | Gly6 | His14 | 34.47 |
| Phe19 | Met13 | 24.06 | Lys16 | Gly8 | 75.82 | Gly38 | Gly9 | 25.11 | Tyr10 | Gly10 | 33.82 |
| Gly2 | Val39 | 23.18 | Lys16 | Gly10 | 41.21 | Gly6 | Ala30 | 23.9 | Tyr10 | Asn11 | 26.59 |
| Gly38 | Leu3 | 21.23 | His13 | Gly8 | 38.77 | Ser12 | Ala42 | 23.47 | Gly9 | Ser8 | 25.12 |
| Asn11 | Gly37 | 20.79 | Arg5 | Val5 | 32.24 | Gly37 | Gly8 | 22.05 | Ser12 | Gln15 | 24.09 |
| Gly10 | Val36 | 20.46 | Leu17 | Leu3 | 31.93 | Ile32 | Gly7 | 20.48 | Gly2 | Gly38 | 22.83 |
| Gly38 | Gly7 | 19.63 | Gly2 | Leu34 | 29.42 | Val24 | Val5 | 18.53 | Met4 | Met35 | 22.73 |
| Ala42 | Asn11 | 19.44 | Ile1 | Asp1 | 29.12 | Val40 | Asn11 | 18.4 | Gly37 | Gly2 | 22.69 |
| Leu3 | Val39 | 18.57 | Val5 | His13 | 27 | Asn11 | Gly38 | 15.83 | Gly10 | Tyr10 | 22.16 |
| Val39 | Leu3 | 18.53 | His13 | Gly6 | 25.1 | Gly7 | Ala30 | 15.12 | Gly7 | Glu11 | 22.06 |
| Ser12 | Val40 | 18.5 | Met4 | Glu3 | 24.52 | Gly38 | Gly8 | 14.83 | Ile1 | Ala42 | 20.81 |
| Asn11 | Gly38 | 17.56 | Lys16 | Ser12 | 24.38 | Val40 | Asn11 | 14.52 | Gln15 | Ser12 | 17.95 |
| Leu34 | Gly10 | 16.53 | Val5 | Phe20 | 21.83 | Ile32 | Gly7 | 14.43 | Gly8 | Glu11 | 17.52 |
| Met13 | Val40 | 16.45 | Phe20 | Gly6 | 21.02 | Gly9 | Val39 | 13.61 | Gly8 | His14 | 17.32 |
| Met13 | Val40 | 16.29 | Phe20 | Met4 | 20.99 | Gly37 | Gly9 | 13.37 | Met4 | Met35 | 17.26 |
| Asn11 | Val36 | 15.5 | Leu17 | Met4 | 20.33 | Met13 | Ile41 | 13.13 | Ile1 | Glu22 | 16.28 |
| Asn11 | Val39 | 15.04 | Ile1 | Glu22 | 18.93 | Val40 | Met13 | 13.11 | Gly8 | Gly9 | 14.64 |
| Val39 | Gly8 | 14.31 | Gly6 | Phe20 | 18.39 | Gly6 | Gly29 | 13.02 | Met4 | Leu34 | 14.62 |
| Ser12 | Val40 | 14.3 | Gly7 | Phe20 | 17.75 | Ser12 | Ile41 | 12.22 | Gly38 | Val5 | 14.57 |
| Gly10 | Val39 | 13.94 | Val5 | Val40 | 16.23 | Val39 | Gly9 | 12.13 | His6 | Gly9 | 14.56 |
| Ala42 | Asn11 | 13.86 | Leu3 | Leu34 | 15.66 | Gly10 | Gly37 | 11.54 | Ile1 | Val40 | 13.66 |
| Val39 | Gly10 | 13.57 | Ala42 | Val5- | 15.58 | Val24 | Gly2 | 11.21 | His14 | Gly6 | 13.33 |
| Gly9 | Leu34 | 13.34 | Phe19 | Ser12 | 15 | Met13 | Phe4 | 11.13 | Gly2 | Gly37 | 13.28 |

| (C) Complex Dock 3 | | | | | |
|--------------------|----------|-------|---------|----------|--------|
| mode I | | | mode II | | |
| Donor | Acceptor | % | Donor | Acceptor | % |
| Gly29 | Gly8 | 35.59 | Lys16 | Met13 | 113.95 |
| His14 | Met4 | 34.55 | Lys16 | Ser12 | 85.66 |
| Leu3 | His14 | 33.62 | Gly6 | Ile41 | 71.12 |
| Ala21 | Gly6 | 30.61 | Ile41 | Met4 | 64.14 |
| Gly8 | Gly25 | 28.55 | Ile1 | Asp1 | 61.12 |
| Ile31 | Gly6 | 27.43 | Ile1 | Asp23 | 53.06 |
| Gly8 | Val24 | 25.38 | Gly38 | Gly2 | 51.16 |
| Gly8 | Asp23 | 23.71 | Met4 | Val39 | 50.76 |
| Ala30 | Gly6 | 22.68 | Gly2 | Asp23 | 40.39 |
| Gly7 | Asp23 | 20.31 | Met4 | Gly37 | 39.68 |
| Leu3 | Tyr10 | 19.11 | Val39 | Gly2 | 39.55 |
| Ile31 | Gly6 | 18.42 | Lys28 | Gly9 | 38.48 |
| Gly10 | Val36 | 18.36 | Val40 | Gly6 | 36.74 |
| Ile31 | Gly9 | 17.03 | Lys28 | Gly8 | 35.36 |
| Val39 | Gly8 | 17.01 | Ile1 | Glu3 | 34.73 |
| Gly10 | Gly37 | 16.75 | Lys28 | Gly6 | 33.79 |
| Gly8 | Val39 | 16.3 | Val40 | Met4 | 33.67 |
| Ile31 | Gly7 | 15.65 | Lys28 | Gly7 | 33.13 |
| Ile31 | Gly8 | 15.46 | Asn27 | Leu3 | 31.98 |
| Gly8 | Lys28 | 14.24 | Leu3 | Lys16 | 30.71 |
| Gly6 | Val24 | 14.08 | Ile1 | Glu3 | 26.98 |
| Gly29 | Gly6 | 14.07 | Ile1 | Glu3 | 25.92 |
| His14 | Leu3 | 13.31 | Gly29 | Gly6 | 24.93 |
| Gly38 | Gly8 | 13.3 | His13 | Met13 | 23.14 |
| Gly7 | Ala21 | 12.79 | Gly6 | Val40 | 23.01 |

Figures:




Figure S1 Analysis of the Zn²⁺ interactions with Glycine, Methionine, and Phenylalanine. The three results of Gly, Met, and Phe interaction are specified by blue, red and green colors respectively. (a) RMSD plotted against time (b) Distance between the OT2 of the carboxyl group and the zinc metal ion (c) LIE free energy estimate of the amino acids-Zn²⁺ interactions




Figure S2 final snapshots of 100 ns interaction between amino acids including Glycine, Methionine, and Phenylalanine with zinc metal ion at 298 K. The atoms of oxygen, carbon, nitrogen, hydrogen, and sulfur are colored by red, cyan, blue, white and yellow respectively. The distances between the oxygen atoms of the carboxyl group (OT1 and OT2) and the zinc metal ion are specified in the final snapshot for all three simulations.




Figure S3 LIE free energy estimate of $\text{A}\beta$ -ligand interactions. Subfigures of (a), (b), and (c), refer to the binding free energy for C1, C2, and C3, respectively. In every subfigure, the first and the second modes are colored as blue and red respectively.




Figure S4 Time development of distances between MET13:OT2 and Zinc metal ion for the six simulations of A β -ligand-Zn $^{2+}$ trilateral interactions. (a), (b) and (c) refer to modes of C1, C2, and C3, respectively. In every subfigure, the first and the second modes are colored as blue and red respectively.